Hologic (NASDAQ:HOLX) is withdrawing its Q2 and FY 2020 guidance, in response to COVID-19 pandemic.
The Company expects Q2 total revenues of $756.1M (-7.6% Y/Y).
Q2 Diagnostics and Breast Health revenues of $319.2M and $307.8M, respectively.
Q2 GYN Surgical revenue of $105.4M.
The company expects to report Q2 results on April 29.
https://seekingalpha.com/news/3558907-hologic-pulls-2020-guidance-amid-covidminus-19
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.